Other new therapies instead reverse the immune tolerance towards cancer through the blockade of negative immune regulators such as PD-1/PD-1L and CTLA4 have enjoyed vast success in clinical trials of NSCLC and bypass the need of targeting EGFR specifically, providing an attractive therapeutic [139,140]. Here, EGFR is linked to cancer.